Telaglenastat + Talazoparib In Prostate Cancer
Public ClinicalTrials.gov record NCT04824937. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With the PARP Inhibitor Talazoparib in Participants With Metastatic Castration-Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this research is to test the effectiveness of an experimental drug combination for people with metastatic castration-resistant prostate cancer (mCRPC). The names of the study drugs involved in this study are: * Telaglenastat (CB-839) * Talazoparib
Study identification
- NCT ID
- NCT04824937
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2021
- Primary completion
- Dec 30, 2021
- Completion
- Dec 30, 2021
- Last update posted
- Mar 31, 2021
2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Prostate Cancer Metastatic trials
Other public records listing Prostate Cancer Metastatic. Sorted by last update posted; newest first. Not a recommendation.
- NCT05067140: A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer Active, not recruiting
- NCT04030338: Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer Active, not recruiting
- NCT07593079: Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Not yet recruiting
- NCT04848337: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer Active, not recruiting
- NCT06136624: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Recruiting
- NCT06171139: Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04824937, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2021 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04824937 live on ClinicalTrials.gov.